Regression of oral proliferative leukoplakia following initiation of ibrutinib therapy in two allogeneic hematopoietic stem cell transplant recipients

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1


  1. 1.

    Mays JW, Fassil H, Edwards DA, Pavletic SZ, Bassim CW. Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis. 2013;19:327–46.

  2. 2.

    Mawardi H, Elad S, Correa ME, Stevenson K, Woo SB, Almazrooa S, et al. Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant. 2011;46:884–91.

  3. 3.

    Hanna GJ, Kofman ER, Shazib MA, Woo SB, Reardon B, Treister NS, et al. Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. Oral Oncol. 2018;81:1–9.

  4. 4.

    Mohty B, Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J. 2011;1:e16–e16.

  5. 5.

    Villa A, Menon RS, Kerr AR, De Abreu Alves F, Guollo A, Ojeda D, et al. Proliferative leukoplakia: Proposed new clinical diagnostic criteria. Oral Dis. 2018;24:749–60.

  6. 6.

    Borgna SC, Clarke PT, Schache AG, Lowe D, Ho MW, McCarthy CE, et al. Management of proliferative verrucous leukoplakia: justification for a conservative approach. Head Neck. 2017;39:1997–2003.

  7. 7.

    Miklos D, Cutler CS, Arora M, Waller E, Jagasia M, Pusic I, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130:2243–50.

  8. 8.

    Torres-Pereira C, Funke V, Giovanini AF, Lemos CA Jr, Amenabar JM, Piazzetta CM. Oral proliferative verrucous leukoplakia (PVL) in a post-bone marrow transplant patient. Biol Blood Marrow Transplant. 2008;14:1197–9.

  9. 9.

    Leite Carvalhaes CL, Nunes Vilela MC, Fernandes KSÁ, Lascane NA, Da Silva Santos PS, Mantesso A, et al. Leukoplakia lesion in a patient with history of graft-versus-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117:e126.

  10. 10.

    Hansen LS, Olson JA, Silverman S Jr. Proliferative verrucous leukoplakia. A long-term study of thirty patients. Oral Surg Oral Med Oral Pathol. 1985;60:285–98.

  11. 11.

    Yagyuu T, Hatakeyama K, Imada M, Kurihara M, Matsusue Y, Yamamoto K, et al. Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions. Oral Oncol. 2017;68:36–43.

  12. 12.

    Sloand EM, Pfannes L, Ling C, Feng X, Jasek M, Calado R, et al. Graft-versus-host disease: role of inflammation in the development of chromosomal abnormalities of keratinocytes. Biol Blood Marrow Transplant. 2010;16:1665–73.

Download references

Author information



Corresponding author

Correspondence to Paolo J. Fantozzi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fantozzi, P.J., Villa, A., Antin, J.H. et al. Regression of oral proliferative leukoplakia following initiation of ibrutinib therapy in two allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant (2020).

Download citation